CAR-T Therapy for Autoimmune Disease Market: By Target (CD19, BCMA, Dual CD19/BCMA, Other B-Cell Targets); Cell Source (Autologous, Allogeneic, In Vivo Engineered); Indication (Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Multiple Sclerosis, Myasthenia Gravis, Others); Development Stage (Preclinical, Clinical, Approved); End User (Academic Medical Centers, Specialty Hospitals, Biopharma)—Market Size, Industry Dynamics, Opportunity Analysis and Forecast For 2026–2035
The CAR-T therapy for autoimmune disease market is estimated at USD 150.7 million in 2025 and is projected to reach USD 9,044.2 million by 2035, growing at a CAGR of 50.6% over the forecast period 2026–2035. Read More
We Are Trusted By These Great Companies!
Last Updated: 10-Sep-2026 | Format: | Report ID: AA09261982